Back to results
US 2024/0252586 A1Published application
Engineered antimicrobial peptides and usage thereof
AssigneePeptilogics, Inc.
InventorsJonathan D. STECKBECK, Bradd N. PICONE, Despina X. DOBBINS
Life of this patent
Estimating the term…
Abstract
Provided in this disclosure are pharmaceutical formulations comprising antimicrobial peptides with a basic pH. Further provided herein are methods of treating or preventing an infection comprising administering pharmaceutical formulations comprising antimicrobial peptides when administered to a subject.
Claims94
A pharmaceutical formulation comprising:
- (a) a peptide or pharmaceutically acceptable salt thereof comprising at least about 70% sequence identity to a polypeptide sequence of:
- Arg-Arg-Trp-Val-Arg-Arg-Val-Arg-Arg-Val-Trp-Arg-Arg-Val-Val-Arg-Val-Val-Arg-Arg-Trp-Val-Arg-Arg (SEQ ID NO:
- 1);
- Arg-Val-Val-Arg-Val-Val-Arg-Arg-Val-Val-Arg-Arg (SEQ ID NO:
- 15);
- Arg-Val-Val-Arg-Val-Val-Arg-Arg-Trp-Val-Arg-Arg (SEQ ID NO:
- 16);
- Arg-Trp-Trp-Arg-Trp-Trp-Arg-Arg-Trp-Trp-Arg-Arg (SEQ ID NO:
- 17);
- Trp-Arg-Arg-Trp-Trp-Arg-Arg-Trp-Trp-Arg-Trp-Trp-Arg-Arg-Trp-Trp-Arg-Arg (SEQ ID NO:
- 18);
- Arg-Arg-Val-Val-Arg-Arg-Val-Arg-Arg-Val-Val-Arg-Arg-Val-Val-Arg-Val-Val-Arg-Arg-Val-Val-Arg-Arg (SEQ ID NO:
- 19);
- Arg-Arg-Trp-Trp-Arg-Arg-Trp-Arg-Arg-Trp-Trp-Arg-Arg-Trp-Trp-Arg-Trp-Trp-Arg-Arg-Trp-Trp-Arg-Arg (SEQ ID NO:
- 20);
- Val-Arg-Arg-Val-Val-Arg-Arg-Val-Val-Arg-Val-Val-Arg-Arg-Val-Val-Arg-Arg-Val-Arg-Arg-Val-Val-Arg-Arg-Val-Val-Arg-Val-Val-Arg-Arg-Val-Val-Arg-Arg (SEQ ID NO:
- 21);
- Val-Arg-Arg-Val-Trp-Arg-Arg-Val-Val-Arg-Val-Val-Arg-Arg-Trp-Val-Arg-Arg-Val-Arg-Arg-Val-Trp-Arg-Arg-Val-Val-Arg-Val-Val-Arg-Arg-Trp-Val-Arg-Arg (SEQ ID NO:
- 22);
- Arg-Arg-Val-Val-Arg-Arg-Val-Arg-Arg-Val-Val-Arg-Arg-Val-Val-Arg-Val-Val-Arg-Arg-Val-Val-Arg-Arg-Val-Arg-Arg-Val-Val-Arg-Arg-Val-Val-Arg-Val-Val-Arg-Arg-Val-Val-Arg-Arg (SEQ ID NO:
- 23);
- Arg-Val-Val-Arg-Val-Val-Arg-Arg-Val-Val-Arg-Arg-Val-Arg-Arg-Val-Val-Arg-Arg-Val-Val-Arg-Val-Val-Arg-Arg-Val-Val-Arg-Arg-Val-Arg-Arg-Val-Val-Arg-Arg-Val-Val-Arg-Val-Val-Arg-Arg-Val-Val-Arg-Arg (SEQ ID NO:
- 24);
- Arg-Val-Val-Arg-Val-Val-Arg-Arg-Trp-Val-Arg-Arg-Val-Arg-Arg-Val-Trp-Arg-Arg-Val-Val-Arg-Val-Val-Arg-Arg-Trp-Val-Arg-Arg-Val-Arg-Arg-Val-Trp-Arg-Arg-Val-Val-Arg-Val-Val-Arg-Arg-Trp-Arg-Val-Val (SEQ ID NO:
- 25), or any combination thereof;
- and
- (b) aqueous sodium bicarbonate.
24 more elements
A pharmaceutical formulation consisting of:
- (a) a peptide or pharmaceutically acceptable salt thereof comprising at least about 70% sequence identity to a polypeptide sequence of:
- Arg-Arg-Trp-Val-Arg-Arg-Val-Arg-Arg-Val-Trp-Arg-Arg-Val-Val-Arg-Val-Val-Arg-Arg-Trp-Val-Arg-Arg (SEQ ID NO:
- 1);
- Arg-Val-Val-Arg-Val-Val-Arg-Arg-Val-Val-Arg-Arg (SEQ ID NO:
- 15);
- Arg-Val-Val-Arg-Val-Val-Arg-Arg-Trp-Val-Arg-Arg (SEQ ID NO:
- 16);
- Arg-Trp-Trp-Arg-Trp-Trp-Arg-Arg-Trp-Trp-Arg-Arg (SEQ ID NO:
- 17);
- Trp-Arg-Arg-Trp-Trp-Arg-Arg-Trp-Trp-Arg-Trp-Trp-Arg-Arg-Trp-Trp-Arg-Arg (SEQ ID NO:
- 18);
- Arg-Arg-Val-Val-Arg-Arg-Val-Arg-Arg-Val-Val-Arg-Arg-Val-Val-Arg-Val-Val-Arg-Arg-Val-Val-Arg-Arg (SEQ ID NO:
- 19);
- Arg-Arg-Trp-Trp-Arg-Arg-Trp-Arg-Arg-Trp-Trp-Arg-Arg-Trp-Trp-Arg-Trp-Trp-Arg-Arg-Trp-Trp-Arg-Arg (SEQ ID NO:
- 20);
- Val-Arg-Arg-Val-Val-Arg-Arg-Val-Val-Arg-Val-Val-Arg-Arg-Val-Val-Arg-Arg-Val-Arg-Arg-Val-Val-Arg-Arg-Val-Val-Arg-Val-Val-Arg-Arg-Val-Val-Arg-Arg (SEQ ID NO:
- 21);
- Val-Arg-Arg-Val-Trp-Arg-Arg-Val-Val-Arg-Val-Val-Arg-Arg-Trp-Val-Arg-Arg-Val-Arg-Arg-Val-Trp-Arg-Arg-Val-Val-Arg-Val-Val-Arg-Arg-Trp-Val-Arg-Arg (SEQ ID NO:
- 22);
- Arg-Arg-Val-Val-Arg-Arg-Val-Arg-Arg-Val-Val-Arg-Arg-Val-Val-Arg-Val-Val-Arg-Arg-Val-Val-Arg-Arg-Val-Arg-Arg-Val-Val-Arg-Arg-Val-Val-Arg-Val-Val-Arg-Arg-Val-Val-Arg-Arg (SEQ ID NO:
- 23);
- Arg-Val-Val-Arg-Val-Val-Arg-Arg-Val-Val-Arg-Arg-Val-Arg-Arg-Val-Val-Arg-Arg-Val-Val-Arg-Val-Val-Arg-Arg-Val-Val-Arg-Arg-Val-Arg-Arg-Val-Val-Arg-Arg-Val-Val-Arg-Val-Val-Arg-Arg-Val-Val-Arg-Arg (SEQ ID NO:
- 24);
- Arg-Val-Val-Arg-Val-Val-Arg-Arg-Trp-Val-Arg-Arg-Val-Arg-Arg-Val-Trp-Arg-Arg-Val-Val-Arg-Val-Val-Arg-Arg-Trp-Val-Arg-Arg-Val-Arg-Arg-Val-Trp-Arg-Arg-Val-Val-Arg-Val-Val-Arg-Arg-Trp-Arg-Val-Val (SEQ ID NO:
- 25), or any combination thereof;
- and
- (b) aqueous sodium bicarbonate.
24 more elements
A kit comprising:
- (i) a first container comprising a peptide or pharmaceutically acceptable salt thereof comprising at least about 70% sequence identity to a polypeptide
- (SEQ ID NO:
- 1)
- Arg-Arg-Trp-Val-Arg-Arg-Val-Arg-Arg-Val-Trp-Arg-
- Arg-Val-Val-Arg-Val-Val-Arg-Arg-Trp-Val-Arg-Arg;
- (SEQ ID NO:
- 15)
- Arg-Val-Val-Arg-Val-Val-Arg-Arg-Val-Val-Arg-Arg;
- (SEQ ID NO:
- 16)
- Arg-Val-Val-Arg-Val-Val-Arg-Arg-Trp-Val-Arg-Arg;
- (SEQ ID NO:
- 17)
- Arg-Trp-Trp-Arg-Trp-Trp-Arg-Arg-Trp-Trp-Arg-Arg;
- (SEQ ID NO:
- 18)
- Trp-Arg-Arg-Trp-Trp-Arg-Arg-Trp-Trp-Arg-Trp-Trp-
- Arg-Arg-Trp-Trp-Arg-Arg;
- (SEQ ID NO:
- 19)
- Arg-Arg-Val-Val-Arg-Arg-Val-Arg-Arg-Val-Val-Arg-
- Arg-Val-Val-Arg-Val-Val-Arg-Arg-Val-Val-Arg-Arg;
- (SEQ ID NO:
- 20)
- Arg-Arg-Trp-Trp-Arg-Arg-Trp-Arg-Arg-Trp-Trp-Arg-
- Arg-Trp-Trp-Arg-Trp-Trp-Arg-Arg-Trp-Trp-Arg-Arg;
- (SEQ ID NO:
- 21)
- Val-Arg-Arg-Val-Val-Arg-Arg-Val-Val-Arg-Val-Val-
- Arg-Arg-Val-Val-Arg-Arg-Val-Arg-Arg-Val-Val-Arg-
- Arg-Val-Val-Arg-Val-Val-Arg-Arg-Val-Val-Arg-Arg;
- (SEQ ID NO:
- 22)
- Val-Arg-Arg-Val-Trp-Arg-Arg-Val-Val-Arg-Val-Val-
- Arg-Arg-Trp-Val-Arg-Arg-Val-Arg-Arg-Val-Trp-Arg-
- Arg-Val-Val-Arg-Val-Val-Arg-Arg-Trp-Val-Arg-Arg;
- (SEQ ID NO:
- 23)
- Arg-Arg-Val-Val-Arg-Arg-Val-Arg-Arg-Val-Val-Arg-
- Arg-Val-Val-Arg-Val-Val-Arg-Arg-Val-Val-Arg-Arg-
- Val-Arg-Arg-Val-Val-Arg-Arg-Val-Val-Arg-Val-Val-
- Arg-Arg-Val-Val-Arg-Arg;
- (SEQ ID NO:
- 24)
- Arg-Val-Val-Arg-Val-Val-Arg-Arg-Val-Val-Arg-Arg-
- Val-Arg-Arg-Val-Val-Arg-Arg-Val-Val-Arg-Val-Val-
- Arg-Arg-Val-Val-Arg-Arg-Val-Arg-Arg-Val-Val-Arg-
- Arg-Val-Val-Arg-Val-Val-Arg-Arg-Val-Val-Arg-Arg;
- (SEQ ID NO:
- 25)
- Arg-Val-Val-Arg-Val-Val-Arg-Arg-Trp-Val-Arg-Arg-
- Val-Arg-Arg-Val-Trp-Arg-Arg-Val-Val-Arg-Val-Val-
- Arg-Arg-Trp-Val-Arg-Arg-Val-Arg-Arg-Val-Trp-Arg-
- Arg-Val-Val-Arg-Val-Val-Arg-Arg-Trp-Arg-Val-Val,
- or any combination thereof;
- and
- (ii) a second container comprising aqueous sodium bicarbonate.
54 more elements
A method of making a pharmaceutical formulation from a kit, wherein the kit comprises:
- (i) a first container comprising a peptide or pharmaceutically acceptable salt thereof comprising at least about 70% sequence identity to a polypeptide sequence of:
- (SEQ ID NO:
- 1)
- Arg-Arg-Trp-Val-Arg-Arg-Val-Arg-Arg-Val-Trp-Arg-
- Arg-Val-Val-Arg-Val-Val-Arg-Arg-Trp-Val-Arg-Arg;
- (SEQ ID NO:
- 15)
- Arg-Val-Val-Arg-Val-Val-Arg-Arg-Val-Val-Arg-Arg;
- (SEQ ID NO:
- 16)
- Arg-Val-Val-Arg-Val-Val-Arg-Arg-Trp-Val-Arg-Arg;
- (SEQ ID NO:
- 17)
- Arg-Trp-Trp-Arg-Trp-Trp-Arg-Arg-Trp-Trp-Arg-Arg;
- (SEQ ID NO:
- 18)
- Trp-Arg-Arg-Trp-Trp-Arg-Arg-Trp-Trp-Arg-Trp-Trp-
- Arg-Arg-Trp-Trp-Arg-Arg;
- (SEQ ID NO:
- 19)
- Arg-Arg-Val-Val-Arg-Arg-Val-Arg-Arg-Val-Val-Arg-
- Arg-Val-Val-Arg-Val-Val-Arg-Arg-Val-Val-Arg-Arg;
- (SEQ ID NO:
- 20)
- Arg-Arg-Trp-Trp-Arg-Arg-Trp-Arg-Arg-Trp-Trp-Arg-
- Arg-Trp-Trp-Arg-Trp-Trp-Arg-Arg-Trp-Trp-Arg-Arg;
- (SEQ ID NO:
- 21)
- Val-Arg-Arg-Val-Val-Arg-Arg-Val-Val-Arg-Val-Val-
- Arg-Arg-Val-Val-Arg-Arg-Val-Arg-Arg-Val-Val-Arg-
- Arg-Val-Val-Arg-Val-Val-Arg-Arg-Val-Val-Arg-Arg;
- (SEQ ID NO:
- 22)
- Val-Arg-Arg-Val-Trp-Arg-Arg-Val-Val-Arg-Val-Val-
- Arg-Arg-Trp-Val-Arg-Arg-Val-Arg-Arg-Val-Trp-Arg-
- Arg-Val-Val-Arg-Val-Val-Arg-Arg-Trp-Val-Arg-Arg;
- (SEQ ID NO:
- 23)
- Arg-Arg-Val-Val-Arg-Arg-Val-Arg-Arg-Val-Val-Arg-
- Arg-Val-Val-Arg-Val-Val-Arg-Arg-Val-Val-Arg-Arg-
- Val-Arg-Arg-Val-Val-Arg-Arg-Val-Val-Arg-Val-Val-
- Arg-Arg-Val-Val-Arg-Arg;
- (SEQ ID NO:
- 24)
- Arg-Val-Val-Arg-Val-Val-Arg-Arg-Val-Val-Arg-Arg-
- Val-Arg-Arg-Val-Val-Arg-Arg-Val-Val-Arg-Val-Val-
- Arg-Arg-Val-Val-Arg-Arg-Val-Arg-Arg-Val-Val-Arg-
- Arg-Val-Val-Arg-Val-Val-Arg-Arg-Val-Val-Arg-Arg;
- or
- (SEQ ID NO:
- 25)
- Arg-Val-Val-Arg-Val-Val-Arg-Arg-Trp-Val-Arg-Arg-
- Val-Arg-Arg-Val-Trp-Arg-Arg-Val-Val-Arg-Val-Val-
- Arg-Arg-Trp-Val-Arg-Arg-Val-Arg-Arg-Val-Trp-Arg-
- Arg-Val-Val-Arg-Val-Val-Arg-Arg-Trp-Arg-Val-Val;
- (ii) a second container comprising aqueous sodium bicarbonate;
- (iii) a third container comprising water;
- and
- (iv) a mixing container;
- wherein method comprises adding the first container, the second container, and the third container into the mixing container, thereby resulting in the pharmaceutical formulation.
57 more elements
A method of preventing or treating an infection in a subject in need thereof, wherein the method comprising locally administering of a pharmaceutical formulation to a site of infection, wherein administration comprises washing, irrigating, debriding, aspirating, or a combination thereof the site of infection, thereby preventing or treating the infection, wherein the pharmaceutical formulation comprises:
- (a) a peptide or pharmaceutically acceptable salt thereof comprising at least about 70% sequence identity to a polypeptide sequence of:
- Arg-Arg-Trp-Val-Arg-Arg-Val-Arg-Arg-Val-Trp-Arg-Arg-Val-Val-Arg-Val-Val-Arg-Arg-Trp-Val-Arg-Arg (SEQ ID NO:
- 1) Arg-Val-Val-Arg-Val-Val-Arg-Arg-Val-Val-Arg-Arg (SEQ ID NO:
- 15);
- Arg-Val-Val-Arg-Val-Val-Arg-Arg-Trp-Val-Arg-Arg (SEQ ID NO:
- 16);
- Arg-Trp-Trp-Arg-Trp-Trp-Arg-Arg-Trp-Trp-Arg-Arg (SEQ ID NO:
- 17);
- Trp-Arg-Arg-Trp-Trp-Arg-Arg-Trp-Trp-Arg-Trp-Trp-Arg-Arg-Trp-Trp-Arg-Arg (SEQ ID NO:
- 18);
- Arg-Arg-Val-Val-Arg-Arg-Val-Arg-Arg-Val-Val-Arg-Arg-Val-Val-Arg-Val-Val-Arg-Arg-Val-Val-Arg-Arg (SEQ ID NO:
- 19);
- Arg-Arg-Trp-Trp-Arg-Arg-Trp-Arg-Arg-Trp-Trp-Arg-Arg-Trp-Trp-Arg-Trp-Trp-Arg-Arg-Trp-Trp-Arg-Arg (SEQ ID NO:
- 20);
- Val-Arg-Arg-Val-Val-Arg-Arg-Val-Val-Arg-Val-Val-Arg-Arg-Val-Val-Arg-Arg-Val-Arg-Arg-Val-Val-Arg-Arg-Val-Val-Arg-Val-Val-Arg-Arg-Val-Val-Arg-Arg (SEQ ID NO:
- 21);
- Val-Arg-Arg-Val-Trp-Arg-Arg-Val-Val-Arg-Val-Val-Arg-Arg-Trp-Val-Arg-Arg-Val-Arg-Arg-Val-Trp-Arg-Arg-Val-Val-Arg-Val-Val-Arg-Arg-Trp-Val-Arg-Arg (SEQ ID NO:
- 22);
- Arg-Arg-Val-Val-Arg-Arg-Val-Arg-Arg-Val-Val-Arg-Arg-Val-Val-Arg-Val-Val-Arg-Arg-Val-Val-Arg-Arg-Val-Arg-Arg-Val-Val-Arg-Arg-Val-Val-Arg-Val-Val-Arg-Arg-Val-Val-Arg-Arg (SEQ ID NO:
- 23);
- Arg-Val-Val-Arg-Val-Val-Arg-Arg-Val-Val-Arg-Arg-Val-Arg-Arg-Val-Val-Arg-Arg-Val-Val-Arg-Val-Val-Arg-Arg-Val-Val-Arg-Arg-Val-Arg-Arg-Val-Val-Arg-Arg-Val-Val-Arg-Val-Val-Arg-Arg-Val-Val-Arg-Arg (SEQ ID NO:
- 24);
- Arg-Val-Val-Arg-Val-Val-Arg-Arg-Trp-Val-Arg-Arg-Val-Arg-Arg-Val-Trp-Arg-Arg-Val-Val-Arg-Val-Val-Arg-Arg-Trp-Val-Arg-Arg-Val-Arg-Arg-Val-Trp-Arg-Arg-Val-Val-Arg-Val-Val-Arg-Arg-Trp-Arg-Val-Val (SEQ ID NO:
- 25), or any combination thereof;
- and
- (b) an aqueous carrier, wherein the aqueous carrier provides a synergistic effect with the peptide or pharmaceutically acceptable salt thereof, wherein the synergistic effect comprises reduces a bacterial burden in the subject to a greater extent as compared to administering (a) or (b) alone.
23 more elements
A method of preventing or treating an infection in a subject in need thereof, wherein the method comprising locally administering of a pharmaceutical formulation to a site of infection, wherein administration comprises washing, irrigating, debriding, aspirating, or a combination thereof the site of infection, thereby preventing or treating the infection, wherein the pharmaceutical formulation consists of:
- (a) a peptide or pharmaceutically acceptable salt thereof comprising at least about 70% sequence identity to a polypeptide sequence of:
- Arg-Arg-Trp-Val-Arg-Arg-Val-Arg-Arg-Val-Trp-Arg-Arg-Val-Val-Arg-Val-Val-Arg-Arg-Trp-Val-Arg-Arg (SEQ ID NO:
- 1);
- Arg-Val-Val-Arg-Val-Val-Arg-Arg-Val-Val-Arg-Arg (SEQ ID NO:
- 15);
- Arg-Val-Val-Arg-Val-Val-Arg-Arg-Trp-Val-Arg-Arg (SEQ ID NO:
- 16);
- Arg-Trp-Trp-Arg-Trp-Trp-Arg-Arg-Trp-Trp-Arg-Arg (SEQ ID NO:
- 17);
- Trp-Arg-Arg-Trp-Trp-Arg-Arg-Trp-Trp-Arg-Trp-Trp-Arg-Arg-Trp-Trp-Arg-Arg (SEQ ID NO:
- 18);
- Arg-Arg-Val-Val-Arg-Arg-Val-Arg-Arg-Val-Val-Arg-Arg-Val-Val-Arg-Val-Val-Arg-Arg-Val-Val-Arg-Arg (SEQ ID NO:
- 19);
- Arg-Arg-Trp-Trp-Arg-Arg-Trp-Arg-Arg-Trp-Trp-Arg-Arg-Trp-Trp-Arg-Trp-Trp-Arg-Arg-Trp-Trp-Arg-Arg (SEQ ID NO:
- 20);
- Val-Arg-Arg-Val-Val-Arg-Arg-Val-Val-Arg-Val-Val-Arg-Arg-Val-Val-Arg-Arg-Val-Arg-Arg-Val-Val-Arg-Arg-Val-Val-Arg-Val-Val-Arg-Arg-Val-Val-Arg-Arg (SEQ ID NO:
- 21);
- Val-Arg-Arg-Val-Trp-Arg-Arg-Val-Val-Arg-Val-Val-Arg-Arg-Trp-Val-Arg-Arg-Val-Arg-Arg-Val-Trp-Arg-Arg-Val-Val-Arg-Val-Val-Arg-Arg-Trp-Val-Arg-Arg (SEQ ID NO:
- 22);
- Arg-Arg-Val-Val-Arg-Arg-Val-Arg-Arg-Val-Val-Arg-Arg-Val-Val-Arg-Val-Val-Arg-Arg-Val-Val-Arg-Arg-Val-Arg-Arg-Val-Val-Arg-Arg-Val-Val-Arg-Val-Val-Arg-Arg-Val-Val-Arg-Arg (SEQ ID NO:
- 23);
- Arg-Val-Val-Arg-Val-Val-Arg-Arg-Val-Val-Arg-Arg-Val-Arg-Arg-Val-Val-Arg-Arg-Val-Val-Arg-Val-Val-Arg-Arg-Val-Val-Arg-Arg-Val-Arg-Arg-Val-Val-Arg-Arg-Val-Val-Arg-Val-Val-Arg-Arg-Val-Val-Arg-Arg (SEQ ID NO:
- 24);
- Arg-Val-Val-Arg-Val-Val-Arg-Arg-Trp-Val-Arg-Arg-Val-Arg-Arg-Val-Trp-Arg-Arg-Val-Val-Arg-Val-Val-Arg-Arg-Trp-Val-Arg-Arg-Val-Arg-Arg-Val-Trp-Arg-Arg-Val-Val-Arg-Val-Val-Arg-Arg-Trp-Arg-Val-Val (SEQ ID NO:
- 25), or combination thereof;
- and
- (b) an aqueous carrier, wherein the aqueous carrier provides a synergistic effect with the peptide or pharmaceutically acceptable salt thereof, wherein the synergistic effect comprises reduces a bacterial burden in the subject to a greater extent as compared to administering (a) or (b) alone.
24 more elements
A method of preventing or treating an infection in a subject in need thereof, wherein the method comprising locally administering of a pharmaceutical formulation to a site of infection, wherein locally administration comprises washing, irrigating, debriding, aspirating, or a combination thereof of the site of infection, thereby preventing or treating the infection, wherein the pharmaceutical formulation comprises:
- (a) a peptide or pharmaceutically acceptable salt thereof comprising at least about 70% sequence identity to a polypeptide sequence of:
- Arg-Arg-Trp-Val-Arg-Arg-Val-Arg-Arg-Val-Trp-Arg-Arg-Val-Val-Arg-Val-Val-Arg-Arg-Trp-Val-Arg-Arg (SEQ ID NO:
- 1);
- Arg-Val-Val-Arg-Val-Val-Arg-Arg-Val-Val-Arg-Arg (SEQ ID NO:
- 15);
- Arg-Val-Val-Arg-Val-Val-Arg-Arg-Trp-Val-Arg-Arg (SEQ ID NO:
- 16);
- Arg-Trp-Trp-Arg-Trp-Trp-Arg-Arg-Trp-Trp-Arg-Arg (SEQ ID NO:
- 17);
- Trp-Arg-Arg-Trp-Trp-Arg-Arg-Trp-Trp-Arg-Trp-Trp-Arg-Arg-Trp-Trp-Arg-Arg (SEQ ID NO:
- 18);
- Arg-Arg-Val-Val-Arg-Arg-Val-Arg-Arg-Val-Val-Arg-Arg-Val-Val-Arg-Val-Val-Arg-Arg-Val-Val-Arg-Arg (SEQ ID NO:
- 19);
- Arg-Arg-Trp-Trp-Arg-Arg-Trp-Arg-Arg-Trp-Trp-Arg-Arg-Trp-Trp-Arg-Trp-Trp-Arg-Arg-Trp-Trp-Arg-Arg (SEQ ID NO:
- 20);
- Val-Arg-Arg-Val-Val-Arg-Arg-Val-Val-Arg-Val-Val-Arg-Arg-Val-Val-Arg-Arg-Val-Arg-Arg-Val-Val-Arg-Arg-Val-Val-Arg-Val-Val-Arg-Arg-Val-Val-Arg-Arg (SEQ ID NO:
- 21);
- Val-Arg-Arg-Val-Trp-Arg-Arg-Val-Val-Arg-Val-Val-Arg-Arg-Trp-Val-Arg-Arg-Val-Arg-Arg-Val-Trp-Arg-Arg-Val-Val-Arg-Val-Val-Arg-Arg-Trp-Val-Arg-Arg (SEQ ID NO:
- 22);
- Arg-Arg-Val-Val-Arg-Arg-Val-Arg-Arg-Val-Val-Arg-Arg-Val-Val-Arg-Val-Val-Arg-Arg-Val-Val-Arg-Arg-Val-Arg-Arg-Val-Val-Arg-Arg-Val-Val-Arg-Val-Val-Arg-Arg-Val-Val-Arg-Arg (SEQ ID NO:
- 23);
- Arg-Val-Val-Arg-Val-Val-Arg-Arg-Val-Val-Arg-Arg-Val-Arg-Arg-Val-Val-Arg-Arg-Val-Val-Arg-Val-Val-Arg-Arg-Val-Val-Arg-Arg-Val-Arg-Arg-Val-Val-Arg-Arg-Val-Val-Arg-Val-Val-Arg-Arg-Val-Val-Arg-Arg (SEQ ID NO:
- 24);
- Arg-Val-Val-Arg-Val-Val-Arg-Arg-Trp-Val-Arg-Arg-Val-Arg-Arg-Val-Trp-Arg-Arg-Val-Val-Arg-Val-Val-Arg-Arg-Trp-Val-Arg-Arg-Val-Arg-Arg-Val-Trp-Arg-Arg-Val-Val-Arg-Val-Val-Arg-Arg-Trp-Arg-Val-Val (SEQ ID NO:
- 25), or any combination thereof;
- and
- (b) aqueous sodium bicarbonate.
24 more elements
A method of preventing or treating an infection in a subject in need thereof, wherein the method comprising locally administering of a pharmaceutical formulation to a site of infection, wherein locally administration comprises washing, irrigating, debriding, aspirating, or a combination thereof of the site of infection, thereby preventing or treating the infection, wherein the pharmaceutical formulation consists of:
- (a) a peptide or pharmaceutically acceptable salt thereof comprising at least about 70% sequence identity to a polypeptide sequence of:
- Arg-Arg-Trp-Val-Arg-Arg-Val-Arg-Arg-Val-Trp-Arg-Arg-Val-Val-Arg-Val-Val-Arg-Arg-Trp-Val-Arg-Arg (SEQ ID NO:
- 1);
- Arg-Val-Val-Arg-Val-Val-Arg-Arg-Val-Val-Arg-Arg (SEQ ID NO:
- 15);
- Arg-Val-Val-Arg-Val-Val-Arg-Arg-Trp-Val-Arg-Arg (SEQ ID NO:
- 16);
- Arg-Trp-Trp-Arg-Trp-Trp-Arg-Arg-Trp-Trp-Arg-Arg (SEQ ID NO:
- 17);
- Trp-Arg-Arg-Trp-Trp-Arg-Arg-Trp-Trp-Arg-Trp-Trp-Arg-Arg-Trp-Trp-Arg-Arg (SEQ ID NO:
- 18);
- Arg-Arg-Val-Val-Arg-Arg-Val-Arg-Arg-Val-Val-Arg-Arg-Val-Val-Arg-Val-Val-Arg-Arg-Val-Val-Arg-Arg (SEQ ID NO:
- 19);
- Arg-Arg-Trp-Trp-Arg-Arg-Trp-Arg-Arg-Trp-Trp-Arg-Arg-Trp-Trp-Arg-Trp-Trp-Arg-Arg-Trp-Trp-Arg-Arg (SEQ ID NO:
- 20);
- Val-Arg-Arg-Val-Val-Arg-Arg-Val-Val-Arg-Val-Val-Arg-Arg-Val-Val-Arg-Arg-Val-Arg-Arg-Val-Val-Arg-Arg-Val-Val-Arg-Val-Val-Arg-Arg-Val-Val-Arg-Arg (SEQ ID NO:
- 21);
- Val-Arg-Arg-Val-Trp-Arg-Arg-Val-Val-Arg-Val-Val-Arg-Arg-Trp-Val-Arg-Arg-Val-Arg-Arg-Val-Trp-Arg-Arg-Val-Val-Arg-Val-Val-Arg-Arg-Trp-Val-Arg-Arg (SEQ ID NO:
- 22);
- Arg-Arg-Val-Val-Arg-Arg-Val-Arg-Arg-Val-Val-Arg-Arg-Val-Val-Arg-Val-Val-Arg-Arg-Val-Val-Arg-Arg-Val-Arg-Arg-Val-Val-Arg-Arg-Val-Val-Arg-Val-Val-Arg-Arg-Val-Val-Arg-Arg (SEQ ID NO:
- 23);
- Arg-Val-Val-Arg-Val-Val-Arg-Arg-Val-Val-Arg-Arg-Val-Arg-Arg-Val-Val-Arg-Arg-Val-Val-Arg-Val-Val-Arg-Arg-Val-Val-Arg-Arg-Val-Arg-Arg-Val-Val-Arg-Arg-Val-Val-Arg-Val-Val-Arg-Arg-Val-Val-Arg-Arg (SEQ ID NO:
- 24);
- Arg-Val-Val-Arg-Val-Val-Arg-Arg-Trp-Val-Arg-Arg-Val-Arg-Arg-Val-Trp-Arg-Arg-Val-Val-Arg-Val-Val-Arg-Arg-Trp-Val-Arg-Arg-Val-Arg-Arg-Val-Trp-Arg-Arg-Val-Val-Arg-Val-Val-Arg-Arg-Trp-Arg-Val-Val (SEQ ID NO:
- 25), or any combination thereof;
- and
- (b) aqueous sodium bicarbonate.
24 more elements
Dependencies are inferred from the claim text.